Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatments from those with peptic ulcer disease? A systematic review

Table 3 Characteristics of triple therapies consisting of a PPI, clarithromycin and amoxicillin.

Refs	Combination regimens	Dose	Treatmentduration (d)	Eradication rate (ITT)		P
				PUD	NUD
				N/T.N (%)	N/T.N (%)
22	Ome/Cla/Amo	20 mg b.i.d./500 mg b.i.d./1 g b.i.d.	7	134/161 (83.2)	34/42 (81)
7	Ome/Cla/Amo	20 mg b.i.d.1/500 mg b.i.d./1 g b.i.d.	7	60/65 (92.3)	30/50 (60)
9	PPI/Cla/Amo	PPI b.i.d./500 mg b.i.d./1 g b.i.d .	7	27/34 (79.4)	15/21 (71.4)
11	Rab/Cla/Amo	20 mg b.i.d./500 mg b.i.d./1 g b.i.d.	7	101/135 (74.8)	288/392 (73.5)
20	Pan/Cla/Amo	40 mg b.i.d./500 mg b.i.d./1 g b.i.d.	7	27/29 (93.1)	13/19 (68.4)
27	Rab/Cla/Amo	20 mg b.i.d./500 mg b.i.d./1 g b.i.d.	7	82/101 (81.2)	68/93 (73)
				431/525 (82.1)	448/617 (72.6)2
10	Ome/Cla/Amo	40 mg b.i.d./800 mg b.i.d./2 g b.i.d.	7	87/98 (88.8)	6/6 (100)	0.388
10	Ome/Cla/Amo	40 mg b.i.d./1.6 g b.i.d./2 g b.i.d.	7	51/51 (100)	49/50 (98)	0.313
8	Lan/Cla/Amo	30 mg b.i.d./500 mg b.i.d./1 g b.i.d.	10	13/13 (100)	65/71 (91.6)
21	Ome/Cla/Amo	20 mg b.i.d./500 mg b.i.d./1 g b.i.d.	10	63/96 (65.6)	20/27 (74.1)
27	Rab/Cla/Amo	20 mg b.i.d./500 mg b.i.d./1 g b.i.d.	10	75/97 (77.3)	78/99 (78.8)
27	Ome/Cla/Amo	20 mg b.i.d./500 mg b.i.d./1 g b.i.d.	10	77/103 (74.8)	68/103 (73.1)
				231/309 (74.8)	231/300 (77)3

Ome, omeprazole; Lan, lansoprazole; Pan, pantoprazole; Rab, rabeprazole; Cla, clarithromycin; Amo, amoxicillin; daily; q.d., daily; b.i.d., twice daily. ¹Omeprazole was used for 2 wk. PUD, peptic ulcer disease; NUD, non-ulcer dyspepsia; PPI b.i.d., PPI in standard dose.

²RR (95%CI): 1.15 (1.01-1.29).

³RR (95%CI): 1.03 (0.95-1.12). N/T.N, number/total number.